Sino Biopharmaceutical (HKG: 1177) announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) has entered into a strategic biosimilar collaboration with European pharmaceutical company STADA Arzneimittel AG (STADA). The partnership centers on the pembrolizumab biosimilar TQB3570 as its inaugural product and establishes a scalable framework extendable to other oncology and immunology biosimilars — with STADA receiving an exclusive license across the EU, Switzerland, the UK, and the CIS and holding options for the United States and GCC markets.
Deal Snapshot
| Item | Detail |
|---|---|
| Parties | Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ, subsidiary of Sino Biopharmaceutical, HKG: 1177) and STADA Arzneimittel AG |
| Inaugural Product | TQB3570 — pembrolizumab biosimilar (anti‑PD‑1 monoclonal antibody) |
| Framework | Scalable collaboration extendable to other oncology and immunology biosimilars |
| Upfront Payment | Received by CTTQ (amount not disclosed) |
| Milestones | Up to €53 million in development, regulatory, and commercial milestone payments |
| Profit Sharing | Double‑digit profit share to CTTQ on TQB3570 sales in licensed territories |
| Exclusive License Territories | European Union, Switzerland, United Kingdom, Commonwealth of Independent States (CIS) |
| Pipeline Option | STADA may add up to three additional biosimilar molecules in oncology and immunology |
| Regional Options | STADA holds options for the United States and Gulf Cooperation Council (GCC) member states |
| Announcement Date | 28 Sep 2026 |
Roles & Responsibilities
| Function | Responsible Party |
|---|---|
| Research, development, manufacturing, commercial supply (licensed territories) | CTTQ |
| Marketing authorizations | STADA |
| Exclusive sales & marketing rights (licensed territories) | STADA |
Drug Profile & Strategic Rationale
- Molecule: TQB3570 (R&D code) — a biosimilar candidate to pembrolizumab, the anti‑PD‑1 monoclonal antibody that anchors one of global oncology’s largest franchises and is among the world’s best‑selling cancer drugs.
- Biosimilar Opportunity: As originator patent protection on pembrolizumab approaches expiry later this decade, biosimilar entrants are positioning for a market that spans dozens of tumor types and combination regimens worldwide.
- Division of Labor: CTTQ leads R&D, manufacturing, and commercial supply for the licensed territories, while STADA — one of Europe’s largest independent generics and specialty pharmaceutical companies — holds the marketing authorizations and exclusive sales and marketing rights, pairing Chinese development and supply scale with European commercial reach.
- Scalable Framework: Beyond the inaugural pembrolizumab biosimilar, the agreement’s option for up to three additional molecules across oncology and immunology creates a multi‑asset pipeline pathway under a single partnership structure.
- Geographic Optionality: STADA’s U.S. and GCC options preserve expansion room into the world’s largest pharmaceutical market and fast‑growing Gulf markets, exercisable at STADA’s discretion; terms and timing not disclosed.
Market Impact & Outlook
- CTTQ’s Biosimilar Engine: The deal monetizes CTTQ’s biologics development and manufacturing platform via upfront economics, up to €53 million in milestones, and a double‑digit profit share — a capital‑light route to European revenue without building its own commercial footprint.
- STADA’s Specialty Push: Securing exclusive European rights to a pembrolizumab biosimilar advances STADA’s strategy of moving beyond small‑molecule generics into high‑value biosimilars at a time when European tenders for biologic copies are rapidly forming.
- Sino Biopharmaceutical Globalization: The collaboration extends the group’s international partnerships and validates its subsidiary’s quality systems against European regulatory expectations.
- Competitive Landscape: Multiple global developers are pursuing pembrolizumab biosimilars; early European licensing positions STADA to compete for first‑wave tender access once originator exclusivity lapses.
- Execution Risk: Biosimilar development requires demonstrated comparability to the reference product and European regulatory approval; development timelines, trial status of TQB3570, and option exercise deadlines were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the development, regulatory approval, and commercialization of TQB3570 and any additional biosimilar molecules under the CTTQ–STADA collaboration, including the exercise of pipeline and regional options. Actual results may differ materially due to risks including biosimilarity demonstration, regulatory outcomes in the EU and option territories, manufacturing scale‑up, competitive dynamics, and tender and pricing environments.-Fineline Info & Tech
